Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) – open-label extension to TACTT3
2013-001527-39Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Oct 2013
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Keyzilen in tinnitus, sponsored by Altamira Therapeutics. Started Oct 2013; status: completed.
02
Drugs
Keyzilen
03
Conditions
tinnitus
Beyond the preview
Go deeper on 2013-001527-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001527-39.